ecancermedicalscience

Case Report

Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma

13 Mar 2008
PF Ferrucci, A Vanazzi, C Crosta, G Pruneri, C Grana, M Bartolomei, G Paganelli, G Martinelli

Treatment modalities for resistant/relapsing gastric mucosa associated lymphoid tissue (MALT) non-Hodgkin’s lymphoma (NHL) are not yet well standardized. In the past, most patients were treated surgically with a gastrectomy, while, more recently, radiotherapy and systemic approaches (chemotherapy and immunotherapy) have been used with improving results.

Here, we report the case of a patient affected by MALT NHL resistant to antibiotics, chemotherapy and immunotherapy, who achieved a durable complete remission after radio-immunotherapy treatment with Zevalin (90Y ibritumomab-tiuxetan), administered in a single-standard dose. This observation must be confirmed on a larger series but suggests that radio-immunotherapy may be a valid approach in treating relapsing MALT NHL patients, or those resistant to conventional therapies, so avoiding more aggressive and toxic approaches.

Related Articles

Uchenna Simon Ezenkwa, Mohammed Ibrahim Imam, Maimuna Orahachi Yusuf, Abdullahi Sani Giade, Iragbogie Al-Mustapha Imoudu, Dauda Abubakar Katagum, Bala Muhammad Audu
Abhinav Bansal, Ekta Dhamija, Sheragaru Hanumanthappa Chandrashekhara, Ranjit Kumar Sahoo
Debdeep Dey, Bhagat Singh Lali, Paromita Roy, Divya Midha, Indu Arun, Lateef Zameer, Anand Bardia, Geetashree Mukherjee